-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Securities Code: 000788 Securities Short: Peking University Pharmaceutical Announcement No : 2014-35, Notice of Progress in Major Asset Restructuring of Peking University Pharmaceutical Co., Ltd The Company and all members of the Board of Directors guarantee that the contents of the announcement are true, accurate and complete, and that there are no false records, misleading statements or major omissions. On April 25, 2014, Beida Pharmaceutical Co., Ltd (hereinafter referred to as the "Company") disclosed the Notice of suspension of the Board of Directors of Peking University Pharmaceutical Co., Ltd on major asset restructuring (Announcement No 20: 2014-20) on the China Securities News, Securities Times, Shanghai Securities Daily, securities daily and the News .S website of the Giant
Tide After the suspension of trading, the Company disclosed the Notice of Progress in The Significant Asset Restructuring of Peking University Pharmaceutical Co., Ltd on May 6, 2014, May 13, 2014 and May 20, 2014 respectively (Announcement No 2014-25, 2014-26 and 2014-30, respectively) On May 23, 2014, the Company issued the Notice on the Planning of the Expiration of the Suspension of Major Assets Reorganization (Notice No 2014-31), which continued to be suspended from the market on May 23, 2014 During the continuing suspension period, the Company disclosed the Notice of Progress in The Significant Asset Restructuring of Peking University Pharmaceutical Co., Ltd on May 30, 2014 and June 10, 2014, respectively (Announcement No 2014-33 and 2014-34) The details of the above disclosure are detailed in the Company's announcement. As of the date of this announcement, all parties concerned are actively studying and demonstrating and refining the major asset restructuring plan, and improving the relevant due diligence, audit, evaluation and other work Due to the ongoing relevant procedures, there is still uncertainty about the relevant matters, in order to avoid abnormal fluctuations in the company's share price, and effectively safeguard the interests of investors, according to the Measures for the Administration of Major Asset Reorganization of Listed Companies and the relevant provisions of the Shenzhen Stock Exchange on the handling of major asset restructuring business of listed companies, the company's shares will continue to be suspended. During the suspension period, the Company will pay full attention to the progress of the matter, and in accordance with the relevant provisions of the CSRC and the Shenzhen Stock Exchange to timely fulfill the information disclosure obligations, every five trading days issued the above-mentioned asset restructuring matters of the progress of the announcement, please pay attention to the investment risks of investors. This announcement is made. Board of Directors of Peking University Pharmaceutical Co., Ltd June 16, 2014